Clinical Trials Browser

Phase 1/2 × Lymphoma, Non-Hodgkin × Dexamethasone × Clear all

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

NCT01381692 2021-10-04

Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT00299182 2021-09-21

Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma

Phase 1/2 Completed

50 enrolled 11 charts

Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT03892421 2021-05-18

Outpatient Administration of R-DHAP in Relapsed/Refractory Non-Hodgkin Lymphoma

Phase 1/2 Completed

22 enrolled

Lymphoid

Lymphoma, Non-Hodgkin

NCT01983969 2020-01-27

Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma

Phase 1/2 Completed

61 enrolled 10 charts

Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin

Clinical Trials

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma

Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma

Outpatient Administration of R-DHAP in Relapsed/Refractory Non-Hodgkin Lymphoma

Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma